Your essential biotech, medtech, and pharma recap — no noise, just what matters.

GSK is making a deliberate choice not to compete in the GLP-1 weight-loss race. Instead, the company is building a cardiometabolic strategy around the complications of obesity rather than the weight loss itself. The SiranBio deal is the clearest articulation of this approach. SA030 is a long-acting siRNA that silences ALK7, a protein involved in fat storage and inflammation. In preclinical studies, ALK7 inhibition reduced abdominal fat while preserving lean muscle mass, a combination that GLP-1s have struggled to achieve. SiranBio said SA030 has "a complementary and distinct mechanism to GLP-1 agonists, supporting future combination approaches." The implication is that SA030 could be used alongside Wegovy, Foundayo, or any GLP-1 to address the cardiometabolic risk that persists even after weight loss. GSK is not the only company pursuing ALK7: Arrowhead Pharmaceuticals already has Phase 1/2a data for ARO-ALK7 in combination with Lilly's Zepbound. The $1B deal validates the target. Meanwhile, Bayer broke a five-year pharma M&A drought with its $300M Perfuse acquisition, signaling renewed deal appetite. And Viridian's elegrobart Phase 3 success in thyroid eye disease sets up a filing next year in a market where Amgen's Tepezza currently dominates. 👉 Read Full Analysis

GSK Licenses Fat-Targeting siRNA from SiranBio for Up to $1B GSK

What Happened: GSK entered an exclusive licensing agreement with Suzhou-based SiranBio on May 6 for worldwide rights (excluding Greater China) to SA030, a long-acting siRNA targeting activin receptor-like kinase 7 (ALK7). GSK will pay an undisclosed upfront plus up to $1.005B in development, regulatory, and commercial milestones, plus tiered royalties on net sales. SiranBio will complete Phase 1 studies, after which GSK assumes responsibility for further development, regulatory filings, and commercialization.

The Science: ALK7 is a receptor involved in fat cell (adipocyte) biology. SA030 uses adipocyte-directed delivery to silence ALK7 in fat tissue, which in preclinical models reduced abdominal visceral fat while preserving lean muscle mass and improved insulin sensitivity, blood lipid profiles, and fat cell-driven inflammation. SiranBio described a "long-acting profile" supporting low-frequency dosing. The mechanism is distinct from GLP-1s, which primarily work through appetite suppression and delayed gastric emptying.

Executive Impact: GSK CEO Luke Miels told reporters in February: "I think it's going to be very crowded," referring to the GLP-1 space. "Our focus is more on the downstream effects of obesity rather than addressing the actual obesity itself." SA030 fits that strategy. The drug is positioned as complementary to GLP-1s rather than competitive with them. GSK's broader cardiometabolic pipeline includes a Phase 3-ready FGF21 analog for metabolic dysfunction-associated steatohepatitis (MASH). The SiranBio deal is the latest example of a Western pharma company licensing assets from Chinese biotechs, following Lilly/Hengrui (Kailera), AbbVie/Haisco, and others.

Bayer Acquires Perfuse for $300M in First Pharma Deal Since 2021

Bayer acquired Perfuse Therapeutics for $300M upfront, marking the company's first pharma acquisition since 2021, according to BioSpace. Perfuse is developing an eye implant for sustained drug delivery in glaucoma and diabetic retinopathy. The deal expands Bayer's ophthalmology pipeline and addresses a key unmet need: patient compliance with daily eye drops, which remains the primary barrier to effective glaucoma management.

Viridian's Elegrobart Hits Phase 3 in Thyroid Eye Disease VRDN

Viridian Therapeutics reported positive Phase 3 results for elegrobart in thyroid eye disease (TED). The drug normalized the degree of eye protrusion (proptosis) and improved double vision in treated patients. Viridian plans to file for approval in Q1 2027. Elegrobart would compete with Amgen's Tepezza, the only FDA-approved TED treatment, which requires eight infusions over 21 weeks. If elegrobart demonstrates a more convenient dosing profile, it could capture meaningful market share. The TED market is expected to grow as diagnosis rates improve.

👉 Read Full Analysis

The GLP-1 market is projected to exceed $200B by 2030. But GLP-1s have a problem: patients lose muscle mass along with fat. A meaningful portion of weight lost on GLP-1 therapy is lean mass, including muscle. For older patients or those with sarcopenia risk, this is a significant clinical concern.

ALK7 inhibition could solve this. Preclinical data from SiranBio show that silencing ALK7 reduces abdominal (visceral) fat while preserving lean mass. The mechanism targets fat cell biology directly rather than working through appetite or gut motility. That means ALK7 inhibitors could be used as add-ons to GLP-1 therapy: the GLP-1 suppresses appetite and drives weight loss, while the ALK7 inhibitor ensures the weight that comes off is fat, not muscle.

Two companies are pursuing this:

SiranBio/GSK: SA030, long-acting siRNA with adipocyte-directed delivery. Phase 1 in progress. GSK takes over after Phase 1 completion. Up to $1B in milestones.

Arrowhead Pharmaceuticals: ARO-ALK7, RNAi therapy. Phase 1/2a data in combination with Lilly's Zepbound already available. More advanced clinically than SA030.

If ALK7 inhibition works in humans the way it works in preclinical models, the combination of GLP-1 + ALK7 inhibitor could become the standard of care for obesity. That would create a multi-billion dollar market for ALK7 drugs that is additive to, not competitive with, the GLP-1 franchise. GSK's bet is that being first to market with a complementary mechanism is more valuable than being fifth to market with a GLP-1.

💊 GSK's Contrarian Play

Every major pharma company has entered or attempted to enter the GLP-1 weight-loss market. Pfizer tried and failed with danuglipron. Amgen is developing MariTide. AstraZeneca acquired multiple obesity assets. Roche licensed CT-996. The result is what Miels called "very crowded."

GSK chose a different path: address the complications of obesity (MASH, cardiovascular disease, kidney disease, metabolic syndrome) rather than compete on weight loss directly. The portfolio includes the FGF21 analog for MASH (Phase 3 ready), SA030 for cardiometabolic fat reduction (Phase 1), and Shingrix revenue to fund the build.

The logic: the TAM for obesity complications may be larger than the TAM for weight loss drugs, because most obese patients develop complications whether or not they take a GLP-1. And the competitive landscape is far less crowded. If SA030 works, GSK could own a category that every GLP-1 patient is a candidate for.

📊 Viridian vs. Tepezza

Amgen's Tepezza (teprotumumab) is a multi-billion dollar franchise as the only FDA-approved treatment for thyroid eye disease. The drug requires eight IV infusions over 21 weeks.

Viridian's elegrobart hit Phase 3 with proptosis normalization and double vision improvement. If the dosing is more convenient (fewer infusions, subcutaneous option, shorter treatment course), elegrobart could take significant share from Tepezza. Key caveat: Tepezza is deeply entrenched with ophthalmologists and endocrinologists. Switching from a known therapy to a new one requires both clinical differentiation and commercial execution. Viridian's Q1 2027 filing timeline means an approval could come in late 2027 or early 2028.

🎯 Catalyst Calendar: May 2026 Forward

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →